ApppI: triphosphoric acid 1-adenosin-5'-yl ester 3-(3-methylbut-3-enyl 
INTRODUCTION
The majority of human peripheral T cells of the γδ type express a T cell receptor (TCR) comprising Vγ9 and Vδ2 variable regions. These usually represent 1 to 10% of circulating T lymphocytes, expand and release inflammatory cytokines in response to diverse infectious agents such as mycobacteria, bacteria and parasites (1) . They also display cytotoxicity towards diverse tumor cells including laboratory tumor lines (Daudi Burkitt's lymphoma, RPMI-8226 myeloma) and multiple cancer lines from patients with, among others, lung, prostate, liver or kidney cancers (2) (3) (4) .
Metabolites which stimulate Vγ9Vδ2 T cells in a TCR-dependent manner have been purified from mycobacteria and called phosphoantigens because they consist in a short alkyl chain and a terminal pyrophosphate group(5-7). The most powerful natural antigen reported so far is hydroxyl dimethylallyl pyrophosphate (HDMAPP), a metabolite produced by microbial organisms through the deoxylulose pathway, an alternative bacterial route to the isoprenoid precursor isopentenyl pyrophosphate (IPP) (8) (9) (10) . Pyrophosphorylated antigens can directly activate Vγ9Vδ2 T cells and do not absolutely require to be presented by specialized antigen presenting cells nor to be displayed on MHC or CD1 antigens (7, 11) .
Nucleotidic derivatives of phosphoantigens have been purified from mycobacteria and have been found to stimulate Vγ9Vδ2 cells (5, 6) . Multiple synthetic antigens analogous to pyrophosphorylated compounds as well as nucleotidic variants have been studied and some of them proved to be powerful stimulants of Vγ9Vδ2 T cells (12) (13) (14) .
The precise mechanism underlying phosphoantigen recognition is still unclear. Structureactivity correlation studies of synthetic phosphoantigens indicated that, although short alkyls such as ethyl pyrophosphate display some activity, optimal structures contain five carbon atoms and one double bond (15) . Belmant et al. reported that the β-phospho-ester bond in pyrophosphorylated antigens must be cleavable(16) and a recent study by Boedec et al.
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reported the strong stereospecificity of structural alkyl variants (17) . Whether this reflects constraints for binding to the TCR or to a putative presentation molecule is unknown.
TCR gene transfer experiments indicate that phosphoantigen recognition by Vγ9Vδ2 T cells is TCR-dependent (11) . Nevertheless, a direct interaction between the TCR and phosphoantigens is only indirectly supported by structure-function correlations (18) (19) (20) and molecular interaction models (21) . In these studies, aminoacids in the gamma chain complementarity determining region-3 were found essential for phosphoantigen recognition.
The presence of APCs improves direct Vγ9Vδ2 T cell responses to phosphoantigens (22) but their exact contribution is only partially characterized. Analyses with strong pyrophosphorylated agonist antigens such as bromohydrin pyrophosphate, or HDMAPP (22) (23) (24) have shown that to some extent these antigens can be captured by APCs and confer stable stimulatory activity, indicating that they can be somehow displayed on the cell surface as on stimulatory tumors. A mechanism for phosphoantigen presentation is however supported by recent experiments showing binding of soluble Vγ9Vδ2 tetramers on APCs pulsed with HDMAPP. This revealed a direct and antigen-specific recognition of the membrane of pulsed cells which was dependent on a trypsin-sensitive structure (24, 25) .
Tumor cells such as Daudi Burkitt's lymphoma produce weak phosphoantigens through the mevalonate pathway. The major stimulatory compound, IPP, is overproduced in some tumors following hyper-activation of the mevalonate pathway (26, 27) . IPP can also accumulate in cells after treatment with aminobisphosphonates through inhibition of the mevalonate pathway enzyme farnesyl pyrophosphate synthase, resulting in an increased sensitivity to Vγ9Vδ2 T cell cytolytic activity. Aminobisphosphonates also induce intracellular accumulation of ApppI, an adenine nucleotide derivative of IPP in macrophages (28) . As the structure of this compound is reminiscent of bacterial phosphoantigens such as TubAg3/4 and other analogous synthetic nucleotide derivatives with
Nucleotidic antigens for Vγ9Vδ2 cells 5 stimulatory activity, we have studied its biological activity on Vγ9Vδ2 T cells (6) . This revealed unique properties for this nucleotidic phosphoantigen, making this type of compound of particular interest for in vivo administration. We show evidence that nucleotidic antigens are naturally produced in tumor cells and can play a major role in their stimulatory activity towards Vγ9Vδ2 lymphocytes.
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MATERIALS AND METHODS

Antibodies and other reagents
Anti-TCRVδ2-FITC (IMMU360) and CD3-PE (UCHT1) were from BeckmanCoulter, anti-IFNγ-PE (25273) from R&D systems, and anti-CD107a-PE (H4A3) from BDPharmingen. Apyrase, Crotalus adamanteus venom nucleotide pyrophosphatase (NPP) and other reagents were from Sigma Aldrich except Isopentenyl Pyrophosphate (Isoprenoids LC, Tampa, Florida, USA) and ApppI (see below). Apyrase and NPP were used in cellular and biochemical assays at the concentration of 0.2U/ml and 0.02U/ml respectively.
Synthesis of ApppI
The procedure was adapted from Ryu et al. (29) . Briefly, 110 mg (0.2 mmol) of ATP (sodium salt) were converted into the corresponding tetrabutylammonium salt then dissolved in dry acetonitrile (2 ml). To this mixture a solution of isopentenyl tosylate (1 eq., 48 mg) was added in dry acetonitrile (2 ml). The reaction mixture was stirred at room temperature overnight and concentrated. The oily residue was purified on a DEAE sephadex column using a gradient of triethylammonium bicarbonate buffer (TEAB, pH 6.9, 0.2 to 1M). The fractions of interest were evaporated under vacuum, and passed through an ion-exchange Dowex (Na + form) column to give ApppI (1-(adenosin-5'-yl) 3-(3-methylbut-3-enyl) triphosphoric diester)
as sodium salt with a final yield of 45%. ApppI was stored at -20°C. Aliquots were reconstituted in molecular biology grade water and stored at -80°C. In some preparations, HPLC analysis of reconstituted product revealed the presence of 5-10% ADP (presumably from spontaneous degradation). ADP does not affect responses of Vγ9Vδ2 cells in stimulations. This was however checked additionally in control experiments in which this contaminating product was removed by apyrase treatment. To this end, ApppI was pre-treated for 1h with 0.2U/ml apyrase and the enzyme was then inactivated by heating at 100°C for 10 minutes.
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Generation of DCs.
PBMCs from healthy donors were sorted for CD14 + cells using a MACS column (Miltenyi Biotec). DCs were obtained by culturing CD14 + cells in six-well plates (3x10 6 cells/ ml) for 7 days in AIM-V serum-free medium (Invitrogen) supplemented with GM-CSF (100 ng /ml; Novartis) and interleukin-13 (IL-13, 50 ng /ml). Fresh IL-13 was added again after 4 days of culture. The phenotype of iDCs was monitored as described previously (30) and was as follows: CD1a cell activation assay using a T cell:APC ratio of 1:1.
Proliferation assay
PBMCs were stimulated as described for polyclonal Vγ9Vδ2 T cell lines establishment, collected at the indicated times and stained for 30min at 4°C with anti- 
CD107 expression assay for cytolytic function
Experiments were performed as previously described (31) 
HPLC analysis of nucleotidic compounds
For NPP and apyrase sensitivity assays, reaction mixes containing nucleotidic compounds were adjusted to 200µL with water and products were separated by HPLC (System Gold, Beckman Coulter) on a PL-SAX anion exchange column (1000Å, 5µm, 50x4.6mm from Polymer Labs Varian, Marseille, France) using water (A) and 1M
(NH 4 ) 2 HPO 4 , pH 3.5 (B) and the following elution gradient: 0-1 min: 0% B; 1-11 min: 0% to 30% B; 11-13 min: 100% B; 13-20min: 100% A. Eluted nucleotides were detected by monitoring UV absorbance at 260nm. To evaluate phosphatase sensitivity, ApppI and ATP (100µM final concentration) were incubated for 1h at 37°C in 20µl RPMI in the presence of 0.2U/ml apyrase or 0.02U/ml nucleotide pyrophosphatase before analysis. was then tested for stimulatory activity on Vγ9Vδ2 T cell microcultures.
Mass Spectrometry
Mass spectrometry was performed using an LCQ ion-trap mass spectrometer (Finnigan MAT, San Jose,CA). Nano electrospray analysis was performed using a nanospray ESI source (The Protein Analysis Co., Odense, Denmark). Palladium and gold-coated glass capillaries (Proxeon Biosystems, Odense, Denmark) were filled with 3 µL of analyte solution and positioned using a stereomicroscope at a distance of 1 mm to the opening of the heated transfer capillary kept at a temperature of 150°C. A nebulizer gas was not necessary in this spray mode. The nanospray needle voltage was set to 700 V. Samples were analyzed in the negative ion mode. ApppI (m/z 574) was fragmented using the following parameters : parent ion isolation width, 3 m/z; collision energy, 30%; activation Qz, 0.25; activation time, 30 ms. MS 3 analysis of the ApppI fragment at m/z 408 was performed using the following parameters : parent ion isolation width, 3 m/z; collision energy, 33%; activation Qz, 0.25.
Analysis was performed with the Xcalibur 1.2 software (Thermo Electron, San Jose, CA).
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RESULTS
Direct stimulation of γδ T cells with nucleotidic phosphoantigens
The adenylated derivative of IPP, namely triphosphoric acid 1-adenosin-5'-yl ester 3-(3-methylbut-3-enyl) ester, will be referred to as ApppI. In this compound the isopentenyl moiety is linked to the γ-phosphate of ATP instead of being linked to a pyrophosphate group (Fig.1) . When added in a PBMC culture, ApppI induced the selective expansion of Vγ9Vδ2 T cells and the culture reached homogeneity (~94%) in 3 weeks, as it is the case for most phosphoantigens ( Fig.2A) . Although IPP and ApppI both induce proliferation and intracellular IFN-γ production, ApppI required a 5 to 10-fold higher molar concentration for a similar effect on Vγ9Vδ2 T cell expansion from PBMCs (Fig.2B ). The adenylated derivative was also less bioactive than IPP for the stimulation of lymphokine production by Vγ9Vδ2 T cell, with half maximum responses obtained at ~30μM instead of ~1μM for IPP (Fig.2C ).
Both compounds induced the cytotoxicity machinery as evidenced by the surface expression of the lysosomal marker CD107a although IPP induced again a stronger stimulation (Fig.2D) .
Addition of ApppI to IPP slightly increased stimulation, indicating that ApppI does not compete with IPP and has no toxic activity on responder cells (Fig.2E) .
Effect of phosphatases on ApppI responses
The phosphate groups of IPP are sensitive to terminal phosphatases such as alkaline phosphatase (5, 14) or apyrase. Conversely ApppI is expected to be resistant to degradation by the same enzymes. Indeed, treatment of ApppI with apyrase did not change its HPLC profile whereas ATP used as a control for enzyme activity is completely hydrolyzed in similar (33)). PPADS completely abolished the weak spontaneous response to ApppI in the absence of exogenous NPP, confirming that this response is due to partial conversion of ApppI into IPP in the culture medium. PPADS had no effect on the CD3-mediated stimulation, excluding a non-specific toxicity of this compound (Fig.4C) . Altogether, these data indicate that ApppI has no significant intrinsic stimulatory activity and requires conversion into IPP for the stimulation of Vγ9Vδ2 T cells in the absence of APCs.
Effect of tumoral APCs on phosphoantigen-mediated stimulation
It is largely documented that Vγ9Vδ2 T cell stimulation is increased by the presence of bystander APCs (22) . However, although strong agonist pyrophosphorylated antigens can be Nucleotidic antigens for Vγ9Vδ2 cellspulsed on antigen presenting cells(23, 24), this is generally considered as poorly efficient even on dendritic cells (34, 35) . When RPMI-8226 cells, which are week stimulatory tumors were added in cultures of Vγ9Vδ2 T cells and phosphoantigens, we observed a synergistic activation which was more pronounced with ApppI than with IPP (Fig.5A) . This prompted us to compare the pulsing efficiency of these two antigens on different APCs. We first compared the ability of IPP and ApppI to be pulsed on tumor lines which are not professional APCs.
K562 and RPMI-8226 myeloma cell lines have weak spontaneous stimulatory activity, whereas Daudi has a strong spontaneous stimulatory activity for Vγ9Vδ2 T cells. All three cell lines were incubated overnight with both antigens, extensively washed and used for stimulation. Although pulsing with both antigens increased the stimulatory activity of tumors, pulsing with ApppI was again more efficient than with IPP, and ApppI-pulsed tumors were stronger stimulators than cells pulsed with the same molar concentration of IPP (Fig.5B) .
These results could be explained by an effect of ApppI similar to aminobisphosphonate blockade of farnesyl pyrophosphate synthase. If this was the case, ApppI effect would be abolished by simultaneous treatment of tumors with lovastatin, preventing accumulation of endogenous IPP (26) . Fig.5C shows that lovastatin treatment abolishes Daudi spontaneous stimulatory potential and K562 sensitization with pamidronate but has no effect on K562 sensitization with ApppI. Thus ApppI does not act as an inhibitor of farnesyl pyrophosphate synthase.
In order to determine if the acquisition of stimulatory activity by tumor cells required an active process, we studied the effect of temperature and cytoskeleton integrity on pulse efficiency. We used RPMI-8226 cells and short pulsing conditions (2h) which confer stable stimulatory activity without cell alteration when varying the temperature of pulse or with drug addition during pulsing. Pulsing was abrogated when performed at 4°C or on cells which were previously treated with the actin polymerization inhibitor cytochalasin D (Fig.5D ). This
Nucleotidic antigens for Vγ9Vδ2 cellsindicates that pulsing is not simply due to passive adsorption, requires an active mechanism and involves cytoskeletal components, indicative of an active process. Finally, a specific TCR engagement following ApppI recognition on K562 cells is substantiated by a massive TCR aggregation on the T cell surface (Fig.5E ) as well as subsequent TCR downmodulation by FACS analysis (not shown).
ApppI-pulsed cells behave as classical Vγ9Vδ2 target cell lines
As the direct stimulation of Vγ9Vδ2 T cells by ApppI can be modulated by addition of NPP and apyrase, it was important to check the effect of such treatments on the stimulation by pulsed cells. These enzymes were thus added in T cell stimulation assays using either Daudi cells or RPMI-8226 cells pulsed with pamidronate or ApppI (Fig.5F ). In all cases, stimulation with tumor cells was completely resistant to treatment with apyrase and NPP whereas direct simulation was sensitive to phosphatases. Thus the antigen was not recognized in soluble form, was somehow processed to become resistant to these enzymes and was stably presented Thus, if present, ApppI content is below the detection level in K562 cells. As a control, a similar analysis of pamidronate-stimulated K562 extracts unequivocally revealed the presence of ApppI (Suppl. fig.S1 ).
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DISCUSSION
When studying the inhibitory effect of aminobisphosphonates, Monkkonnen et al.
found that these compounds induced the intracellular accumulation of ApppI which presents pro-apoptotic properties on macrophages and osteoclasts. They also provided evidence that this nucleotidic metabolite arose in cells following farnesyl pyrophosphate synthase inhibition and IPP accumulation and a tRNA synthase activity was proposed to be responsible for IPP to ApppI conversion (28, 37) . The possibility that ApppI is somehow involved in the stimulatory effect of tumors on Vγ9Vδ2 lymphocytes was however never investigated before, and although many nucleotidic derivatives of phosphoantigens have been studied, ApppI has never been tested.
We show here that ApppI efficiently stimulates Vγ9Vδ2 T cells when added in PBMC cultures and is thus comparable to other phosphoantigens. However ApppI has no intrinsic stimulatory activity on Vγ9Vδ2 T cells in the absence of APCs, requiring cleavage of the α-β phosphoester bond and IPP release for activity. This is apparently at odds with previous reports indicating that nucleotide addition had little effect on phosphoantigen activity.
However, although it is not excluded that isopentenyl pyrophosphate derivatives display specific properties, in previous reports, the activity of nucleotidic antigens was evaluated in the presence of APCs (12, 14) . Another peak of activity was detected in the same biological extracts in the absence of apyrase or NPP treatment. As this was sensitive to apyrase, it is probably related to the presence of stimulatory pyrophosphate antigens including IPP. This is in agreement with the data of Gober et al (26) although we could not undoubtedly identify IPP in our samples. This may be due to differences in the sample preparation or sensitivity of MS equipment.
Thus, both nucleotidic and non-nucleotidic antigens may be responsible for tumor stimulatory activity. ApppI ultimately requires re-hydrolysis into IPP and the latter might be the only biologically relevant antigenic form for Vγ9Vδ2 T cell stimulation. However, we
propose that IPP to ApppI conversion has two biologically important consequences. 1) ApppI represents an inactive "storage" form of phosphoantigen which may bind to carrier proteins and may be protected from degradation. Thus storage of antigens as nucleotidic derivatives might prolong their half-life and immunogenicity or allow there intracellular transportation.
Moreover, the activity revealed by NPP treatment of cell extracts is higher than that of apyrase-sensitive fractions indicating that this antigenic material is not marginal. 2) Even if
ApppI does not present any direct stimulatory activity, it is more readily captured and displayed as a stimulatory antigen by cells. After sensitization with ApppI, tumors acquire a Nucleotidic antigens for Vγ9Vδ2 cellsstimulatory activity which is resistant to phosphatases and in this respect are similar to naturally stimulating tumors.
Based on these observations, we propose that tumoral phosphoantigens are in fact transported and displayed on the cell surface of tumors in the form of nucleotidic derivatives and are stably associated with a presentation structure. Such presentation mechanism is supported by classical demonstrations of cell-cell contact requirement (34, 38) and the recent demonstration that soluble recombinant TCR constructs bind the tumor cell surface after exposition of cells to HDMAPP (24) . Although the antigen used in the latter quoted experiments were not nucleotidic derivatives, it is quite possible that part of the antigen has been converted into a nucleotidic derivative and exposed in this form on the cell surface, either covalently bound or strongly associated to a presentation structure.
It remains that ApppI is not active directly and requires final conversion to IPP to activate T cells. However, this process could conceivably be achieved by cell-surface associated and tightly regulated NPPs(39). Thus, nucleotidic derivatives of phosphoantigens may represent important intermediates in a possible phosphoantigen processing mechanism, although direct evidence of phosphoantigens on cell membranes is still actively searched for.
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